(Q35893471)

11 August 2017

1 reference

title

The age gap between patients in clinical studies and in the general population: a pitfall for dementia research (English)

1 reference

11 August 2017

0 references

0 references

Niels Schoenmaker

1

1 reference

11 August 2017

Willem A Van Gool

series ordinal

2

1 reference

11 August 2017

publication date

1 October 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

3

1 reference

11 August 2017

issue

10

1 reference

11 August 2017

page(s)

627-630

1 reference

The magnitude of dementia occurrence in the world

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Randomized pilot study of nimesulide treatment in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

High-dose estradiol improves cognition for women with AD: results of a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Amyloid precursor protein in platelets of patients with Alzheimer disease: effect of acetylcholinesterase inhibitor treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Donepezil therapy in clinical practice: a randomized crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Estrogen therapy and noncognitive psychiatric signs and symptoms in elderly patients with dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Research evaluation and prospective diagnosis of dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Effect of oral administration of L-arginine on senile dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Mifepristone (RU 486) for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Memantine in moderate-to-severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

No additional benefit of HRT on response to rivastigmine in menopausal women with AD.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Assessment of low-flow CSF drainage as a treatment for AD: results of a randomized pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

DHEA treatment of Alzheimer's disease: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Alzheimer Disease in the US Population

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Reduced apolipoprotein epsilon 4 allele frequency in the oldest old Alzheimer's patients and cognitively normal individuals.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

The two faces of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Apolipoprotein E, Dementia, and Cortical Deposition of β-Amyloid Protein

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Psychometrically matched measures of global cognition, memory, and executive function for assessment of cognitive decline in older persons

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Age at onset and visuocognitive disturbances in Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Age at onset and language disturbances in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Age at onset and regional cerebral glucose metabolism in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

The overlap between Alzheimer's disease and vascular dementia: the role of white matter changes.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Alzheimer's disease: differences in technetium-99m HMPAO SPECT scan findings between early onset and late onset dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Association of early-onset Alzheimer's disease with an interleukin-1? gene polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Interleukin-1B polymorphism is associated with age at onset of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

EEG power spectrum differences in early and late onset forms of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Eligibility of Alzheimer's disease clinic patients for clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

Impact of referral bias on clinical and epidemiological studies of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900884-1

7 January 2021

10.1016/S1474-4422(04)00884-1

Identifiers

DOI

1 reference

11 August 2017

1 reference